VNRX-5024 / VenatoRx - LARVOL DELTA

VNRX-7145-102: VNRX-7145 Drug-Drug Interaction in Healthy Adult Volunteers (clinicaltrials.gov) - P1; N=53; Completed; Sponsor: Venatorx Pharmaceuticals, Inc.; Recruiting ➔ Completed

Clinical • Trial completion

VNRX-7145-102: VNRX-7145 Drug-Drug Interaction in Healthy Adult Volunteers (clinicaltrials.gov) - P1; N=54; Recruiting; Sponsor: Venatorx Pharmaceuticals, Inc.; Trial completion date: Aug 2021 ➔ Nov 2021; Trial primary completion date: Aug 2021 ➔ Nov 2021

Clinical • Trial completion date • Trial primary completion date

VNRX-7145 Drug-Drug Interaction in Healthy Adult Volunteers (clinicaltrials.gov) - P1; N=42; Recruiting; Sponsor: Venatorx Pharmaceuticals, Inc.; Not yet recruiting ➔ Recruiting

Enrollment open

VNRX-7145 Drug-Drug Interaction in Healthy Adult Volunteers (clinicaltrials.gov) - P1; N=42; Not yet recruiting; Sponsor: Venatorx Pharmaceuticals, Inc.

Clinical • New P1 trial

VNRX-5024 Safety and PK in Healthy Adult Volunteers (clinicaltrials.gov) - P1; N=36; Completed; Sponsor: VenatoRx Pharmaceuticals, Inc.; Recruiting ➔ Completed

Clinical • Trial completion

VNRX-5024 Safety and PK in Healthy Adult Volunteers (clinicaltrials.gov) - P1; N=36; Recruiting; Sponsor: VenatoRx Pharmaceuticals, Inc.; Suspended ➔ Recruiting; Trial completion date: Jul 2020 ➔ Dec 2020; Initiation date: Feb 2020 ➔ Jul 2020; Trial primary completion date: Jul 2020 ➔ Dec 2020

Clinical • Enrollment open • Trial completion date • Trial initiation date • Trial primary completion date

VNRX-5024 Safety and PK in Healthy Adult Volunteers (clinicaltrials.gov) - P1; N=36; Suspended; Sponsor: VenatoRx Pharmaceuticals, Inc.; Recruiting ➔ Suspended

Clinical • Trial suspension